Less Peripheral Sensory Neuropathy with Shorter-term Oxaliplatin-based Chemotherapy Less Peripheral Sensory Neuropathy with Shorter-term Oxaliplatin-based Chemotherapy
Patients with advanced colon cancer face a lower risk of developing long-term peripheral sensory neuropathy (PSN) with a three-month rather than a six-month regimen of oxaliplatin-based adjuvant chemotherapy, according to results from the ACHIEVE phase 3 trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 23, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

New Results Released from the ACHIEVE Study
The ACHIEVE study is one of six that are part of a global collaborative effort to evaluate the  noninferiority of 3-month vs 6-month oxaliplatin-based adjuvant chemotherapy in patients with stage III colon cancer. (Source: CancerNetwork)
Source: CancerNetwork - September 17, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

FBS-Put it to Work
Priced RightWe provide, to our customers, the sameFetal Bovine Serum (FBS) we use in ourdefined media. This FBS enriched media is used in culturing all our human 2 and 3-D based Assays. Our FBS is of the highest quality and priced right at $379/500 ml.Here're some recent publications referencing its use.Gabriela Fernandes, Stephen T Vanyo, Shahad Bakheet Alsharif, Sebastiano Andreana, Michelle B Visser, Rosemary Dziak, Ph.D.Strontium Effects on Human Gingival Fibroblasts. https://doi.org/10.1563/aaid-joi-D-18-00253Douglas Dickinson, Shannon Xayaraj, Sarah Dickinson, Xueling Shao, and Stephen Hsu.  Effect of ...
Source: Neuromics - June 27, 2019 Category: Neuroscience Tags: 3-D Cell based Assays Cell Cultures FBS Fetal Bovine Serum Source Type: news

Novel Neoadjuvant Approach May Boost Surgical Success in Pancreatic Cancer Novel Neoadjuvant Approach May Boost Surgical Success in Pancreatic Cancer
In the majority of studied patients with locally advanced pancreatic cancer, total neoadjuvant treatment with fluorouracil, leucovorin, oxaliplatin and irinotecan (FOLFIRINOX) along with losartan and chemoradiation allowed complete tumor removal, according to a single-arm phase 2 trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 10, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

ASCO: Low - Dose Chemo Benefits Advanced Gastroesophageal Cancer
Elderly, frail receiving 60 percent of oxaliplatin/capecitabine dose have noninferior PFS, less toxicity (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 3, 2019 Category: Cancer & Oncology Tags: Gastroenterology, Oncology, Pharmacy, Geriatrics, Conference News, Source Type: news

Does Oxaliplatin Improve Survival Over Cisplatin in Advanced Gastric Cancer?
Researchers tested the novel oral fluoropyrimidine derivative S-1 plus oxaliplatin vs S-1 plus cisplatin in patients with diffuse-type or mixed-type advanced gastric adenocarcinoma. (Source: CancerNetwork)
Source: CancerNetwork - June 3, 2019 Category: Cancer & Oncology Authors: Lauren M. Dembeck Source Type: news

Sucking Ice Chips Cuts Oral Side Effects of Oxaliplatin Chemo
Benefits include less trouble eating and fewer symptom - related negative effects on quality of life (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - April 24, 2019 Category: Cancer & Oncology Tags: Gastroenterology, Oncology, Pharmacy, Journal, Source Type: news

Sucking Ice Chips Cuts Oral Side Effects of Oxaliplatin Chemo
WEDNESDAY, April 24, 2019 -- Chemotherapy patients who suck on ice chips during treatment with oxaliplatin infusion have less trouble with eating and drinking cold things, fewer negative effects on quality of life due to oral symptoms, and a shorter... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 24, 2019 Category: Pharmaceuticals Source Type: news

Active ingredient of aconite root against peripheral neuropathic pain is identified as neoline
(Nagoya City University) Aconite root is used in East Asian traditional medicines to treat pain. Since its toxicity, it is used after heat-processing for detoxifying. The present study revealed that processed aconite root could relief neuropathic pain in murine peripheral neuropathy model induced by oxaliplatin, paclitaxel, or partial ligation of the sciatic nerve (Seltzer model), and identified that its active ingredient is not benzoylmesaconine, a degraded compound of toxic mesaconitine, but neoline, a stable compound by detoxifying heat-processing. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - April 10, 2019 Category: Biology Source Type: news

Science Saturday: Fruit flies rise to the occasion
Fishing them out of a drink, you may not see the benefit of fruit flies. But they are a vital scientific model, and at Mayo Clinic, they are helping researchers investigate a debilitating chemotherapy side effect: nerve damage called "peripheral neuropathy." "The platinum drugs -- cisplatin, carboplatin, oxaliplatin -- are the [most common] drugs used [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - April 6, 2019 Category: Databases & Libraries Source Type: news

Modified-FOLFIRINOX Beneficial in Resected Pancreatic Cancer
WEDNESDAY, Dec. 19, 2018 -- For patients with resected pancreatic cancer, adjuvant therapy with a modified regimen of chemotherapy with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX), compared with gemcitabine, results in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 19, 2018 Category: Pharmaceuticals Source Type: news

Neuromics FBS at 259 USD/500 ml.
Only 2 Weeks LeftWe wanted to get ourFBS in the hands of more cell culturing experts. Our low pricing has accelerated purchasing of this culture supplement.More importantly, we are pleased with the positive feedback. Here are some recentreviews.Linda S.on BirdEye  ★★★★★9 days agoMy experience with Neuromics was very positive. I asked for a sample of FBS and after to use the FBS I received. Peter T.on BirdEye ★★★★★month agoI purchased FBS from Neuromics. It was shipped to Canada without any problems. It arrived safely and still frozen. Cells grow well in the product. Customer ser...
Source: Neuromics - December 15, 2018 Category: Neuroscience Tags: FBS Fetal Bovine Serum Source Type: news

The Adjuvant Treatment of Stage III Colon Cancer: Might Less Be More?
In this article, we review the findings of the IDEA study and discuss the optimal duration of oxaliplatin-based adjuvant chemotherapy using patient-based risk factors. (Source: CancerNetwork)
Source: CancerNetwork - September 18, 2018 Category: Cancer & Oncology Authors: James J. Lee, MD, PhD, Edward Chu, MD Source Type: news

Second-Line Irinotecan/Cetuximab/Ramucirumab Combo Ups PFS in Advanced CRC
John SchieszerJun 6, 2018A combination of irinotecan, cetuximab, and ramucirumab may boost PFS in advanced CRC, when given after failure of oxaliplatin-and-bevacizumab –based therapy. (Source: CancerNetwork)
Source: CancerNetwork - June 7, 2018 Category: Cancer & Oncology Authors: A Source Type: news

ASCO: mFOLFIRINOX Improves Survival in Pancreatic Cancer
MONDAY, June 4, 2018 -- The oxaliplatin, leucovorin, irinotecan, and 5-fluorouracil (mFOLFIRINOX) regimen is associated with longer median disease-free and overall survival in pancreatic ductal adenocarcinoma; and, receiving chemotherapy before... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 4, 2018 Category: Pharmaceuticals Source Type: news

A3AR Agonists May Help Prevent Chemotherapy-Induced Neuropathic Pain
A highly selective small molecule A3AR agonist blocked development of oxaliplatin-induced neuropathic pain without interfering with anticancer effects. (Source: CancerNetwork)
Source: CancerNetwork - April 13, 2018 Category: Cancer & Oncology Authors: John Schieszer Tags: Colorectal Cancer Gastrointestinal Cancer News Source Type: news

'I'm so lucky my cancer was spotted after budget cuts hit screening' says LORD LANSLEY
LAST Monday, I sat in a chair in a medical day unit while chemotherapy medication went into my vein. A drug called oxaliplatin which, with daily tablets of capecitabine to follow, are my ongoing treatment for bowel cancer. (Source: Daily Express - Health)
Source: Daily Express - Health - April 4, 2018 Category: Consumer Health News Source Type: news

3, 6 Month Adjuvant CAPOX Equally Effective for Colon Cancer
THURSDAY, March 29, 2018 -- For patients with stage III colon cancer, three months of capecitabine and oxaliplatin (CAPOX) therapy is not noninferior to six months of therapy overall, according to a study published in the March 20 issue the New... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 30, 2018 Category: Pharmaceuticals Source Type: news

Palmitoylation of {delta}-catenin promotes kinesin-mediated membrane trafficking of Nav1.6 in sensory neurons to promote neuropathic pain
Palmitoylation of -catenin is critical to synapse plasticity and memory formation. We found that -catenin palmitoylation is also instrumental in the development of neuropathic pain. The abundances of palmitoylated -catenin and the palmitoyl acyltransferase DHHC3 were increased in dorsal root ganglion (DRG) sensory neurons in rat models of neuropathic pain. Inhibiting palmitoyl acyltransferases or decreasing -catenin abundance in the DRG by intrathecal injection of 2-bromopalmitate or shRNA, respectively, alleviated oxaliplatin or nerve injury–induced neuropathic pain in the rats. The palmitoylation of -catenin, which...
Source: Signal Transduction Knowledge Environment - March 27, 2018 Category: Science Authors: Zhang, X.-L., Ding, H.-H., Xu, T., Liu, M., Ma, C., Wu, S.-L., Wei, J.-Y., Liu, C.-C., Zhang, S.-B., Xin, W.-J. Tags: STKE Research Articles Source Type: news

Less Is More: Patients With Colon Cancer Get a Chemo Break Less Is More: Patients With Colon Cancer Get a Chemo Break
Data show that 3 months of oxaliplatin-based chemotherapy is as effective as 6 months but has less toxicity, good news for patients with colon cancer.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 4, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Will Adjuvant Oxaliplatin Data Change Practice in CRC? Will Adjuvant Oxaliplatin Data Change Practice in CRC?
Dr John Marshall previews the GI cancer studies being presented at ASCO with his picks for the ones to watch, and predicts that a plenary presentation may be practice-changing.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 26, 2017 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Adjuvant GEMOX Did Not Improve RFS for Localized Biliary Tract Cancer
Adjuvant chemotherapy for biliary tract cancer using GEMOX (gemcitabine/oxaliplatin) was feasible, but did not result in an improved recurrence-free survival or quality of life compared with surveillance in the phase III PRODIGE 12-ACCORD 18 trial. (Source: CancerNetwork)
Source: CancerNetwork - January 23, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Conferences/ASCO 2017 Gastrointestinal Cancers Symposium Liver, Gallbladder, and Biliary Tract Cancers News Source Type: news

Middle-Aged Man With Acute Thrombocytopenia Subsequent to Fluorouracil and Oxaliplatin Chemotherapy for Colorectal Cancer
A 44-year-old patient with a history of stage IIB colorectal cancer at the hepatic flexure, invading the duodenum and pancreas, was initially diagnosed in September 2005 and received modified Whipple surgery and 8 cycles of adjuvant chemotherapy with capecitabine and oxaliplatin every 3 weeks. (Source: CancerNetwork)
Source: CancerNetwork - November 15, 2016 Category: Cancer & Oncology Authors: Henning Schade, MD Lindsey Davis, MD Peter Kabos, MD Tags: Case Studies Colorectal Cancer Oncology Journal Source Type: news

High-capacity nanoparticle holds potential for targeted cancer therapies
Image: Jeremiah Johnson Chemists from the Mass. Institute of Technology developed a nanoparticle that they can pack with 3 or more drugs to create custom combination therapies for cancer, according to a study published this week in the Journal of the American Chemical Society. The team also revealed that cisplatin, a powerful anti-cancer drug, doesn’t work using the same DNA-damaging mechanism when delivered via nanoparticle compared to traditional methods. The team uses a unique nanoparticle production method, which they 1st reported in 2014. Instead of trying to load the drugs onto nanoparticles that are already bu...
Source: Mass Device - September 15, 2016 Category: Medical Equipment Authors: Sarah Faulkner Tags: Drug-Device Combinations Oncology Research & Development Mass. Institute of Technology Source Type: news

Colon Cancer With Microsatellite Instability: Adjuvant Chemo Colon Cancer With Microsatellite Instability: Adjuvant Chemo
Is deficient mismatch repair colon cancer resistant to adjuvant 5-fluorouracil plus oxaliplatin?Journal of the National Cancer Institute (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 24, 2016 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Molecule prevents effect of chemotherapy
(Aarhus University Hospital) For the last three years the research team has been working on the development of a so-called biomarker to predict treatment effectiveness. Now the researchers found a molecule which is closely associated with the effect of Oxaliplatin treatment, an anti-cancer drug widely used in the treatment of colorectal cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 16, 2016 Category: Cancer & Oncology Source Type: news

Rectal Cancer: Oxaliplatin-based Preoperative Chemoradiation Rectal Cancer: Oxaliplatin-based Preoperative Chemoradiation
Does preoperative 5 x 5 Gy irradiation and FOLFOX4 consolidation chemotherapy improve outcomes in rectal cancer? Annals of Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 29, 2016 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Oxaliplatin-Based Adjuvant Chemo for Stage III MMR CRC Oxaliplatin-Based Adjuvant Chemo for Stage III MMR CRC
Oxaliplatin-based adjuvant chemotherapy was be better than surgery alone for patients with stage 3 colorectal cancer with mutations in DNA mismatch repair genes. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 22, 2016 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Oxaliplatin Can Be Safely Infused at a Rate of 1 mg/m2/minOxaliplatin Can Be Safely Infused at a Rate of 1 mg/m2/min
A study finds that oxaliplatin can be infused safely at a faster rate than previously determined and hopefully this will result in less overall treatment time and improved patient satisfaction. Journal of Oncology Practice (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 9, 2016 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Researchers Identify Best Drug Therapy for Rare, Aggressive, Pancreatic Cancer
JACKSONVILLE, Fla. — Each year, about 200 to 400 Americans develop pancreatic acinar cell carcinoma, a rare form of pancreatic cancer that has no effective standard of care. A study involving researchers on Mayo Clinic’s Florida and Rochester campuses has found that the chemotherapy drug oxaliplatin is effective in stopping the growth of this cancer. [...] (Source: Mayo Clinic Research News)
Source: Mayo Clinic Research News - May 26, 2016 Category: Research Source Type: news

Debiopharm International SA Has Won Its Patent Infringement Suit for Elplat(R) Against Nippon Kayaku Co., Ltd.
LAUSANNE, Switzerland, March 4, 2016 -- (Healthcare Sales & Marketing Network) -- Debiopharm International SA (Debiopharm), part of Debiopharm Group™, a Swiss-based global biopharmaceutical company today announces that the Tokyo District Court granted Deb... Biopharmaceuticals, Generics, Oncology, LitigationDebiopharm Group, Elplat, Oxaliplatin, Nippon Kayaku Co (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 4, 2016 Category: Pharmaceuticals Source Type: news

New method of drug delivery may be safer and more effective against pancreatic cancer
The overall five-year survival rate for people with pancreatic cancer is just 6 percent, and there is an urgent need for new treatment options. More than 80 percent of pancreatic cancer diagnoses occur too late for surgery, making chemotherapy the only possible treatment. Scientists from the California NanoSystems Institute at UCLA and UCLA’s Jonsson Comprehensive Cancer Center have developed a delivery system for one chemotherapy drug that greatly reduces the occurrence of serious side effects while enhancing the drug’s effectiveness against pancreatic cancer. The approach uses mesoporous silica nanoparticles ...
Source: UCLA Newsroom: Health Sciences - March 2, 2016 Category: Universities & Medical Training Source Type: news

Success of Platinum Desensitization 'Depends on the Agent'Success of Platinum Desensitization 'Depends on the Agent'
Cancer patients receiving oxaliplatin are more likely to experience hypersensitivity reactions during desensitization than those given carboplatin. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 2, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Evaluation of NK1 antagonists for emesis prevention in oxaliplatin chemo: SENRI trial
The SENRI trial has opened the window to evaluate NK1 antagonists for emesis prevention in patients taking oxaliplatin chemotherapy, results of a new study. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - July 1, 2015 Category: Science Source Type: news

Evaluation of NK1 antagonists for emesis prevention in oxaliplatin chemo: SENRI trial
(European Society for Medical Oncology) The SENRI trial has opened the window to evaluate NK1 antagonists for emesis prevention in patients taking oxaliplatin chemotherapy, results of a Japanese study presented today at the ESMO 17th World Congress on Gastrointestinal Cancer 2015 in Barcelona reveal. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 1, 2015 Category: Global & Universal Source Type: news

New prostate cancer treatment has promising results in mice
Conclusion This study has built on the findings of previous research that has suggested B immune cells could have a role in making prostate tumours resistant to chemotherapy. This mouse study further investigated this by looking at different ways to suppress these B cells, using immune therapy or genetic techniques. It found that once these B cells were blocked or removed, chemotherapy was able to attack and destroy aggressive prostate cancer cells in mice. The potential for a new chemoimmunotherapy treatment approach for cancer is promising. However, the study is still at a very early stage. While mice studies can give an...
Source: NHS News Feed - April 30, 2015 Category: Consumer Health News Tags: Cancer Medication Source Type: news

New drug helps achieve almost complete prostate cancer remission in mice 
Scientists at the University of California at San Diego used the drug oxaliplatin to fire up cancer-killing immune cells in mice. There are currently few options for men who have aggressive prostate cancer. (Source: the Mail online | Health)
Source: the Mail online | Health - April 30, 2015 Category: Consumer Health News Source Type: news

No Adjuvant Oxaliplatin for Elderly CRC PatientsNo Adjuvant Oxaliplatin for Elderly CRC Patients
Consensus guidelines offer distinct recommendations for adjuvant and palliative treatments in elderly patients with colorectal cancer, as discussed by Dr David Kerr. Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 15, 2015 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Cost of cancer drugs varies widely based on who;s paying
Uninsured cancer patients are asked to pay anywhere from two to 43 times what Medicare would pay for chemotherapy drugs, according to a new study. Uninsured patients who did not negotiate billed amounts for chemo drugs could expect to pay $6,711 for an infusion of the colorectal cancer drug oxaliplatin. However, Medicare and private health plans only pay $3,090 and $3,616 for the same drug, respectively. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 7, 2015 Category: Science Source Type: news

Second-line Oxaliplatin Benefits Pancreatic Cancer PatientsSecond-line Oxaliplatin Benefits Pancreatic Cancer Patients
Dr Alok Khorana reports on the CONKO study, which shows that patients with pancreatic cancer who receive gemcitabine in first-line therapy benefit from second-line oxaliplatin-based therapy. Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 26, 2015 Category: Consumer Health News Tags: Hematology-Oncology Viewpoint Source Type: news

More Drugs, Better Survival in Metastatic Colon Cancer
(MedPage Today) -- Addition of oxaliplatin to FOLFIRI and bevacizumab doubled 5-year survival. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - January 13, 2015 Category: Primary Care Source Type: news

Secondary analysis of RTOG 0247 demonstrates favorable OS rates for rectal cancer patients
Locally advanced rectal cancer patients who receive preoperative radiation therapy with either irinotecan plus capecitabine or oxaliplatin plus capecitabine have a four-year overall survival rate of 85 percent and 75 percent, respectively, according to a study. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - January 9, 2015 Category: Science Source Type: news

Secondary analysis of RTOG 0247 demonstrates favorable OS rates for rectal cancer patients
(American Society for Radiation Oncology) Locally advanced rectal cancer patients who receive preoperative radiation therapy with either irinotecan plus capecitabine or oxaliplatin plus capecitabine have a four-year overall survival rate of 85 percent and 75 percent, respectively, according to a study published in the January 1, 2015 issue of the International Journal of Radiation Oncology * Biology * Physics, the official scientific journal of the American Society for Radiation Oncology. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 9, 2015 Category: Cancer & Oncology Source Type: news

Sanofi introduces authorised generic version of Eloxatin
Sanofi US has introduced an authorised generic version of Eloxatin (oxaliplatin injection), a platinum-based drug used in combination with infusional 5-fluorouracil / leucovorin. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 14, 2014 Category: Pharmaceuticals Source Type: news

Dorsal Sural Nerve Test Sensitive to Oxaliplatin NeuropathyDorsal Sural Nerve Test Sensitive to Oxaliplatin Neuropathy
Dorsal sural nerve conduction testing is a moderately sensitive and very specific test for early detection of oxaliplatin-induced peripheral neuropathy and beats sural nerve testing. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 13, 2014 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Again, Oxaliplatin Is Toxic and No Benefit in Rectal CancerAgain, Oxaliplatin Is Toxic and No Benefit in Rectal Cancer
Yet another rectal cancer study has found that the addition of oxaliplatin to capecitabine chemoradiation in locally advanced disease gives no short-term postoperative benefit and increases toxicity. Medscape Medical News (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - April 7, 2014 Category: Radiology Tags: Hematology-Oncology News Source Type: news

Mangafodipir treatment for oxaliplatin-associated neuropathy
An unfortunate side effect of the platinum-chemotherapy drug oxaliplatin is the development of neurotoxicity, which can adversely affect a patient's quality of life; therefore, the benefit of oxaliplatin-based therapy must be balanced with prevention of neuropathies. Currently, there are no therapeutic interventions available to relieve oxaliplatin-associated neurological symptoms, which are thought to be a result of reactive oxygen species-associated damage. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 31, 2013 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

IV Calcium, Magnesium Don't Prevent Oxaliplatin NeurotoxicityIV Calcium, Magnesium Don't Prevent Oxaliplatin Neurotoxicity
Infusions of calcium and magnesium (CaMg) do not prevent oxaliplatin-induced sensory neurotoxicity, according to a new trial. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 26, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Evaluation of mangafodipir treatment for oxaliplatin-associated neuropathy
(Journal of Clinical Investigation) In this issue of the Journal of Clinical Investigation, Frédéric Batteux and colleagues at the Laboratoire d'Immunologie evaluated use of the MRI contrast agent mangafodipir, which has antioxidant properties, for relief of oxaliplatin-associated neuropathies. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 20, 2013 Category: Global & Universal Source Type: news

JCI early table of contents for Dec. 20, 2013
(Journal of Clinical Investigation) This release contains summaries, links to PDFs, and contact information for the following newsworthy papers to be published online, Dec. 20, 2013 in the JCI: "Fungal surface protein promotes host cell invasion," "Angiogenic factor secretion by melanocytes associated with pigmentation level," "Nonsense suppression drug restores function in a mouse model of aniridia," "Dysfunctional TGF-beta signaling contributes to Loeys-Dietz syndrome-associated aortic aneurysm," "Evaluation of mangafodipir treatment for oxaliplatin-associated neuropathy,"...
Source: EurekAlert! - Cancer - December 20, 2013 Category: Cancer & Oncology Source Type: news